BioMarin Pharmaceutical Inc (BMRN)

Industry Biotechnology

This stock can be held in an Investment ISA and an Investment Account

Sell

$50.00

Buy

$55.65

arrow-down$-0.30 (-0.54%)

Prices updated at 16 Jun 2026, 00:59 EDT

Prices minimum 15 mins delay

Prices in USD

BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex g ...

NASDAQ

3.07%

NASDAQ

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

our Investment Fees and Charges.

Sector

Healthcare

Industry

Biotechnology

Chairman

Mr. Richard A. Meier

CEO

Mr. Alexander Hardy

Most recent earnings

31 Dec 2025

Fiscal year end

31 Dec 2025

Employees

3,221

Head office

770 Lindaro Street

San Rafael

United States

94901

+1 415 506-6700

ir@bmrn.com

Company website

Key personnel

Owner name chevron-l-regular chevron-r-regular	Salary
Mr. Ian T. Clark Independent Director	0.04m
Mr. Richard A. Meier Chairman of the Board	0.17m
Mr. Timothy P. Walbert Independent Director	0.09m
Dr. Willard H. Dere, M.D. Independent Director	0.11m
Mr. G. Eric Davis Executive Vice President, Chief Legal Officer and Secretary	-
Mr. Robert J. Hombach Independent Director	0.11m
Mr. Brian R. Mueller Executive Vice President and Chief Financial Officer	0.72m
Dr. Athena Countouriotis, M.D. Independent Director	0.10m
Mr. Mark Joseph Enyedy Independent Director	0.10m
Dr. Maykin Ho, PhD Independent Director	0.10m
Ms. Barbara W. Bodem Independent Director	0.09m
Ms. Elizabeth McKee Anderson, M.B.A. Independent Director	0.11m
Dr. Charles Greg Guyer, PhD Chief Technical Officer and Executive Vice President	0.70m
Mr. Alexander Hardy Director, President and Chief Executive Officer	1.13m
Ms. Cristin Hubbard Executive Vice President and Chief Commercial Officer	0.66m
Dr. Gregory R. Friberg, M.D. Executive Vice President and Chief Research and Development Officer	0.71m
Ms. Rashmi Virendra Ramchandani Vice President and Chief Accounting Officer	-

Top 5 shareholders

Owner name chevron-l-regular chevron-r-regular	No. of shares
BlackRock Inc	19,818,301
Vanguard Group Inc	18,127,847
Dodge & Cox	14,561,759
PRIMECAP Management Company	14,194,005
BlackRock Fund Advisors	11,479,514

Director dealings

Date chevron-l-regular chevron-r-regular	Action
01 Dec 2025	-
30 Apr 2025	-
30 Sep 2025	-
01 Aug 2025	-
20 May 2025	-
20 May 2025	-
20 May 2025	-
20 May 2025	-
20 May 2025	-
20 May 2025	-
20 May 2025	-
20 May 2025	-
20 May 2025	-
20 May 2025	-
19 May 2025	-
20 May 2025	-
02 May 2025	-
30 Apr 2025	-
19 Mar 2025	-
17 Mar 2025	-

Please note that past performance is not a reliable indicator of future returns.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.